Hantekang makes CIFTIS debut, signs global nutrition and health pact with Norway’s Aker BioMarine

Summary

Hantekang, a New Zealand operator of specialised nutritional supplement brands, has made its CIFTIS debut and signed a 2026-2027 strategic co-operation agreement with Aker BioMarine, the global leader in krill oil. The agreement was signed at Norway's guest-of-honour showcase and the China-Norway business co-operation seminar, with the partnership spanning New Zealand, Norway and China. Under the deal, the two sides will work together on raw material supply, product development, brand promotion and market channels in 2026 and 2027.

Hantekang will use Aker BioMarine's Antarctic krill oil technology and raw material strengths to expand its premium nutrition portfolio. Aker BioMarine will draw on Hantekang's cross-border supply chain and China market capabilities to deepen its Asia-Pacific footprint. Aker BioMarine said its krill oil products have been used in more than 50 human clinical trials, with annual distribution of 1,500 tonnes, sales into about 60 countries and regions, and more than 400 million krill oil capsules sold worldwide each year.

It plans to reduce carbon emissions by 50 percent by 2030. Hantekang's products cover joint care, gut health, immunity support and cardiovascular care.

Commentary

The strategic partnership between New Zealand supplement brand Hantekang and Norway's Aker BioMarine points local small and medium-sized peers towards a new route to cross-border integration. Hantekang is not a raw materials producer; it is a channel and brand operator. By tapping Aker's technology and scale in Antarctic krill oil — 1,500 tonnes distributed a year and more than 400 million capsules sold annually — it can move quickly into the premium cardiovascular and joint care segments and avoid head-on competition with local dairy and honey products.

For NZ SMEs, the opportunity lies in using their compliance and distribution experience in China to become service providers for Nordic marine ingredients entering the Asia-Pacific, rather than simply selling their own brands. Aker's decision to partner with Hantekang instead of building its own China team reflects the complexity of Chinese distribution channels and shifting regulation in the nutrition and health market. Foreign brands prefer to work with smaller local operators that have on-the-ground capability, creating services trade openings for New Zealand firms able to offer cross-border supply chain, registration and e-commerce operations.

Krill oil is growing quickly, but Chinese consumers are tiring of the 'pure New Zealand' label, and origin stories alone will not sustain a premium. Companies need to turn ESG metrics — such as Aker's 50 percent emissions cut by 2030 — into verifiable supply chain narratives to build trust with buyers and lenders. Whether the partnership translates into sell-through at the counter still depends on how well Hantekang runs its Douyin and Tmall Global channels, not on the signing itself.

Keywords: Hantekang, Aker BioMarine, CIFTIS, strategic co-operation agreement, krill oil, nutritional supplements, cross-border supply chain, China-Norway co-operation, New Zealand, health industry

Summary in Chinese | 摘要

2026年中国国际服务贸易交易会期间，新西兰专业化营养膳食补充剂品牌运营企业汉泰康首次亮相，并与全球磷虾油产业领导者挪威阿克海洋生物正式签署2026-2027年度战略合作协议。签约仪式在挪威主宾国推介活动暨中挪商业合作研讨会上举行，合作跨越新西兰、挪威与中国三地。根据协议，双方将在2026至2027年度围绕原料供应、产品研发、品牌推广与市场渠道展开全方位合作：汉泰康借助阿克海洋生物的南极磷虾油技术及原料优势丰富高端营养产品矩阵，阿克海洋生物依托汉泰康的跨境供应链与中国市场运营能力深化亚太市场布局。

阿克海洋生物披露，其磷虾油产品人体临床试验应用多达50余项，年分销总量达1500吨，产品远销约60个国家和地区，全球磷虾油胶囊年销量超4亿粒，并计划到2030年碳排放削减50%。汉泰康产品线覆盖关节养护、肠道调理、免疫力提升、心血管呵护等全场景健康需求。

Commentary in Chinese | 评论

新西兰营养保健品牌汉泰康与挪威阿克海洋生物的战略合作，为本地中小同行展示了跨境整合的新路径。汉泰康并非原料生产商，而是渠道与品牌运营者，借助阿克在南极磷虾油领域的技术与规模化供应（年分销1500吨、胶囊年销超4亿粒），可快速切入高端心血管与关节养护细分市场，避开与本地乳制品、蜂蜜类产品的同质化竞争。对NZ SME而言，关键在于利用自身对中国市场的合规与分销经验，成为北欧海洋原料进入亚太的“服务商”，而不仅限于自有品牌销售。

另一方面，阿克选择汉泰康而非自建中国团队，反映出中国营养保健市场渠道复杂、法规多变，外资品牌更倾向与具备本地运营能力的中小企业合作，这为有能力提供跨境供应链、注册备案和电商运营的新西兰公司带来服务贸易机会。磷虾油品类虽增长较快，但中国消费者对“纯净新西兰”标签已有认知疲劳，单纯产地故事难以支撑高溢价，企业需要将ESG指标（如阿克2030年减排50%）转化为可验证的供应链叙事，才能在采购和融资中建立信任。汉泰康能否将合作落地为终端动销，仍取决于其在抖音、天猫国际等渠道的精细化运营，而非签约本身。

关键词: 汉泰康, 阿克海洋生物, 服贸会, 战略合作协议, 磷虾油, 营养膳食补充剂, 跨境供应链, 中挪合作, 新西兰, 健康产业

Source: None